Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Associate Director, Scientific Services
Senior Director, Oncology Programs and Partnership Development
Associate Director, Educational Strategy
Senior Director, Educational Strategy
This program is intended for physicians, pharmacists, oncology nurses, and other healthcare providers who care for patients with prostate cancer.
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 08, 2020, through October 07, 2021:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Cabozantinib plus atezolizumab suggested encouraging anticancer activity in metastatic castration-resistant prostate cancer; ESMO coverage from Clinical Care Options (CCO)
Download this short slideset from Clinical Care Options (CCO) the use of androgen deprivation therapy for nonmetastatic or metastatic prostate cancer
Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)
Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.